Incyte announces agreement to acquire Escient Pharmaceuticals for $750m
Incyte has entered into a $750m definitive agreement to acquire Escient Pharmaceuticals and its pipeline of small molecule therapeutics for systemic immune and neuro-immune disorders. The deal gives Incyte access to an oral Mas-related G protein-coupled …